{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:56:31Z","timestamp":1793350591844,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260936"],"award-info":[{"award-number":["No. 82260936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"NATCMs Project of High-level Construction of Key TCM Disciplines","award":["No. zyyzdxk-2023188"],"award-info":[{"award-number":["No. zyyzdxk-2023188"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]},{"name":"Funding for Ph.D. of Guizhou University of Traditional Chinese Medicine","award":["GYZYYFY- BS-2022(02)"],"award-info":[{"award-number":["GYZYYFY- BS-2022(02)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04065-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:30:26Z","timestamp":1751355026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmin","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"5","key":"4065_CR1","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/gut.39.5.690","volume":"39","author":"S Shivananda","year":"1996","unstructured":"Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39(5):690\u20137.","journal-title":"Gut"},{"issue":"1","key":"4065_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"4065_CR3","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","volume":"65","author":"M Gajendran","year":"2019","unstructured":"Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis(). Dis Mon. 2019;65(12):100851.","journal-title":"Dis Mon"},{"issue":"3","key":"4065_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1136\/gutjnl-2018-317572","volume":"69","author":"O Ol\u00e9n","year":"2020","unstructured":"Ol\u00e9n O, Askling J, Sachs MC, Neovius M, Smedby KE, Ekbom A, et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964\u20132014. Gut. 2020;69(3):453\u201361.","journal-title":"Gut"},{"issue":"7","key":"4065_CR5","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jgh.12164","volume":"28","author":"Z Zeng","year":"2013","unstructured":"Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X, Su Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28(7):1148\u201353.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"4065_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","volume":"49","author":"L Du","year":"2020","unstructured":"Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):643\u201354.","journal-title":"Gastroenterol Clin North Am"},{"issue":"10401","key":"4065_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571\u201384.","journal-title":"Lancet"},{"issue":"1","key":"4065_CR8","doi-asserted-by":"publisher","first-page":"103882","DOI":"10.1016\/j.sjbs.2023.103882","volume":"31","author":"ZA Abdulrazaq","year":"2024","unstructured":"Abdulrazaq ZA, Al-Ouqaili MTS, Talib NM. The impact of circulating 25-hydroxyvitamin D and vitamin D receptor variation on leukemia-lymphoma outcome: molecular and cytogenetic study. Saudi J Biol Sci. 2024;31(1):103882.","journal-title":"Saudi J Biol Sci"},{"issue":"3","key":"4065_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/1744666X.2017.1243468","volume":"13","author":"D Pugliese","year":"2017","unstructured":"Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, et al. Anti TNF-\u03b1 therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol. 2017;13(3):223\u201333.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"4065_CR10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"issue":"2","key":"4065_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/MIB.0b013e31828100a4","volume":"19","author":"P Biancheri","year":"2013","unstructured":"Biancheri P, Di Sabatino A, Rovedatti L, Giuffrida P, Calarota SA, Vetrano S, et al. Effect of tumor necrosis factor-\u03b1 blockade on mucosal addressin cell-adhesion molecule-1 in Crohn\u2019s disease. Inflamm Bowel Dis. 2013;19(2):259\u201364.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"4065_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","volume":"69","author":"PJ Koelink","year":"2020","unstructured":"Koelink PJ, Bloemendaal FM, Li B, Westera L, Vogels EWM, van Roest M, et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut. 2020;69(6):1053\u201363.","journal-title":"Gut"},{"issue":"8","key":"4065_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","volume":"10","author":"AD Levin","year":"2016","unstructured":"Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 2016;10(8):989\u201397.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"4065_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/ajg.2011.48","volume":"106","author":"S Rutella","year":"2011","unstructured":"Rutella S, Fiorino G, Vetrano S, Correale C, Spinelli A, Pagano N, et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn\u2019s disease. Am J Gastroenterol. 2011;106(4):762\u201370.","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"4065_CR15","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1097\/MIB.0000000000000533","volume":"21","author":"SM Slevin","year":"2015","unstructured":"Slevin SM, Egan LJ. New insights into the mechanisms of action of anti-tumor necrosis factor-\u03b1 monoclonal antibodies in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(12):2909\u201320.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"4065_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ibd.21697","volume":"18","author":"W Reinisch","year":"2012","unstructured":"Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012;18(2):201\u201311.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"4065_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/pharmaceutics16121577","volume":"16","author":"S Clemente Bautista","year":"2024","unstructured":"Clemente Bautista S, Segarra Cant\u00f3n \u00d3, Padull\u00e9s-Zamora N, Garc\u00eda Garc\u00eda S, \u00c1lvarez Beltr\u00e1n M, Larrosa Garc\u00eda M, et al. Long-term effectiveness and safety of proactive therapeutic drug monitoring of infliximab in paediatric inflammatory bowel disease: a real-world study. Pharmaceutics. 2024;16(12):1577.","journal-title":"Pharmaceutics"},{"issue":"3","key":"4065_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","volume":"2","author":"M Ferrante","year":"2008","unstructured":"Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2(3):219\u201325.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"4065_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/sjg.sjg_145_21","volume":"27","author":"HN Zhao","year":"2021","unstructured":"Zhao HN, Jiang M, Sun MJ, Dai C. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: a meta-analysis. Saudi J Gastroenterol. 2021;27(4):191\u2013200.","journal-title":"Saudi J Gastroenterol"},{"key":"4065_CR20","doi-asserted-by":"publisher","first-page":"104455","DOI":"10.1016\/j.phrs.2019.104455","volume":"148","author":"C Guo","year":"2019","unstructured":"Guo C, Wu K, Liang X, Liang Y, Li R. Infliximab clinically treating ulcerative colitis: a systematic review and meta-analysis. Pharmacol Res. 2019;148:104455.","journal-title":"Pharmacol Res"},{"key":"4065_CR21","unstructured":"Gongchen L, Guoqing L. Comparison of the clinical efficacy of infliximab and mesalamine in the treatment of ulcerative colitis. J Clin Rational Drug Use. 2021,14(29):68\u201370."},{"issue":"36","key":"4065_CR22","first-page":"6","volume":"12","author":"Z Huadong","year":"2015","unstructured":"Huadong Z, Qing S. Infliximab in the treatment of ulcerative colitis in 31 cases. J Cheung Kong University. 2015;12(36):6\u20137.","journal-title":"J Cheung Kong University."},{"issue":"11","key":"4065_CR23","first-page":"59","volume":"14","author":"C Haitao","year":"2014","unstructured":"Haitao C, Yuzhu H, Nian F. Application of infliximab in ulcerative colitis. Pract Integr Med. 2014;14(11):59\u201360.","journal-title":"Pract Integr Med."},{"key":"4065_CR24","unstructured":"Lv Z. Evaluation of the efficacy of infliximab in the treatment of ulcerative colitis. Modern Drug Appl China. 2016;10(24):63\u20134."},{"issue":"23","key":"4065_CR25","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis 2. N Engl J Med. 2005;353(23):2462\u201376.","journal-title":"N Engl J Med"},{"issue":"5","key":"4065_CR26","first-page":"231","volume":"8","author":"A Armuzzi","year":"2004","unstructured":"Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004;8(5):231\u20133.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"4065_CR27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/gut.52.7.998","volume":"52","author":"CS Probert","year":"2003","unstructured":"Probert CS, Hearing SD, Schreiber S, K\u00fchbacher T, Ghosh S, Arnott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998\u20131002.","journal-title":"Gut"},{"issue":"11","key":"4065_CR28","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1097\/00042737-200411000-00014","volume":"16","author":"T Ochsenk\u00fchn","year":"2004","unstructured":"Ochsenk\u00fchn T, Sackmann M, G\u00f6ke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16(11):1167\u201371.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"4065_CR29","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G J\u00e4rnerot","year":"2005","unstructured":"J\u00e4rnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karl\u00e9n P, Gr\u00e4nn\u00f6 C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805\u201311.","journal-title":"Gastroenterology"},{"issue":"3","key":"4065_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","volume":"51","author":"T Kobayashi","year":"2016","unstructured":"Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. J Gastroenterol. 2016;51(3):241\u201351.","journal-title":"J Gastroenterol"},{"issue":"2","key":"4065_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","volume":"7","author":"BE Sands","year":"2001","unstructured":"Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7(2):83\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"4065_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, Colombel JF, Lukas M, Gisbert JP, D\u2019Haens G, Hayee B, et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(2):118\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"15","key":"4065_CR33","first-page":"58","volume":"2017","author":"F Lizhen","year":"2017","unstructured":"Lizhen F. Preliminary analysis of the efficacy of infliximab in the treatment of ulcerative colitis. Chin Prescript Drugs. 2017;2017(15):58\u20139.","journal-title":"Chin Prescript Drugs"},{"issue":"34","key":"4065_CR34","first-page":"144","volume":"2015","author":"C Lingwei","year":"2015","unstructured":"Lingwei C. The therapy effect evaluation of infliximab in ulcerative colitis. Chin Foreign Med Care. 2015;2015(34):144\u20135.","journal-title":"Chin Foreign Med Care"},{"issue":"35","key":"4065_CR35","first-page":"3256","volume":"2014","author":"Z Zhongjing","year":"2014","unstructured":"Zhongjing Z, Yongjie L, Weiqiong X, Shinian Q. Comprarison of efficacy of infliximab and mesalazine in the treatment of ulcerative colitis. Jilin Med. 2014;2014(35):3256\u20137.","journal-title":"Jilin Med"},{"issue":"18","key":"4065_CR36","first-page":"21","volume":"2018","author":"W Fei","year":"2018","unstructured":"Fei W, Bingyong Z. Effect observation of infliximab on ulcerative colitis and effect on the level of inflammatory factors. World\u2019s Newest Med Inform Digest. 2018;2018(18):21\u20132.","journal-title":"World's Newest Med Inform Digest"},{"key":"4065_CR37","first-page":"6092","volume":"3","author":"G Zhuo","year":"2016","unstructured":"Zhuo G, Tingting Y, Bin Z. Efficacy and safety of infliximab and mesalazine in the treatment of ulcerative colitis. Electr J Clin Pharm Lit. 2016;3:6092\u20133.","journal-title":"Electr J Clin Pharm Lit"},{"issue":"29","key":"4065_CR38","first-page":"2283","volume":"2014","author":"S Bailong","year":"2014","unstructured":"Bailong S, Xiaohua Z. Efficacy of infliximab in the treatment of refractory ulcerative colitis. Western China Univ Med. 2014;2014(29):2283\u20135.","journal-title":"Western China Univ Med"},{"key":"4065_CR39","first-page":"20","volume":"1","author":"C Baili","year":"2017","unstructured":"Baili C, Jiangming Q, Kaichun W, Jianqiu S, Jianming X, Zhihua R, Yaozong Y, Huahong W, Zhifen C, Zhaoshen L, Chengwei T, Xiaohua H, Yanyan H, et al. The safety and efficacy of infliximab in patients with active ulcerative colitis in China. Chin J Inflam Bowel Dis. 2017;1:20.","journal-title":"Chin J Inflam Bowel Dis"},{"issue":"9","key":"4065_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3923\/pjbs.2023.472.481","volume":"26","author":"ZA Abdulrazaq","year":"2023","unstructured":"Abdulrazaq ZA, Salih Al-Ouqaili MT, Talib NM. Association between circulating 25-Hydroxy vitamin D receptor and molecular response in multiple myeloma. Pak J Biol Sci. 2023;26(9):472\u201381.","journal-title":"Pak J Biol Sci"},{"issue":"9573","key":"4065_CR41","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641\u201357.","journal-title":"Lancet"},{"issue":"07","key":"4065_CR42","first-page":"404","volume":"36","author":"D Dong","year":"2017","unstructured":"Dong D, Jiani L, Ran Q, Yuan L, Yong Y. Progress in the study of ulcerative colitis. Pharm Res. 2017;36(07):404\u20138.","journal-title":"Pharm Res"},{"issue":"4","key":"4065_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.gtc.2020.08.002","volume":"49","author":"A Bhattacharya","year":"2020","unstructured":"Bhattacharya A, Osterman MT. Biologic therapy for ulcerative colitis. Gastroenterol Clin North Am. 2020;49(4):717\u201329.","journal-title":"Gastroenterol Clin North Am"},{"issue":"6","key":"4065_CR44","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40261-024-01364-0","volume":"44","author":"C Niu","year":"2024","unstructured":"Niu C, Zhang J, Napel M, Boppana LKT, Anas H, Jadhav N, et al. Systematic review with meta-analysis: efficacy and safety of Upadacitinib in managing moderate-to-Severe Crohn\u2019s disease and ulcerative colitis. Clin Drug Investig. 2024;44(6):371\u201385.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"4065_CR45","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","volume":"9","author":"L Lichtenstein","year":"2015","unstructured":"Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806\u201315.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"4065_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/ard.2003.015933","volume":"63","author":"P Sidiropoulos","year":"2004","unstructured":"Sidiropoulos P, Bertsias G, Kritikos HD, Kouroumali H, Voudouris K, Boumpas DT. Infliximab treatment for rheumatoid arthritis, with dose titration based on the disease activity score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis. 2004;63(2):144\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4065_CR47","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107(9):1409\u201322.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"4065_CR48","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/apt.17201","volume":"56","author":"EK Dahl","year":"2022","unstructured":"Dahl EK, Abed OK, Kjeldsen J, Donia M, Svane IM, Dige A, et al. Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2022;56(9):1370\u201382.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"4065_CR49","first-page":"680","volume":"11","author":"G D'Haens","year":"2017","unstructured":"D\u2019Haens G, Reinisch W, Colombel JF, Panes J, Ghosh S, Prantera C, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s disease treated with infliximab [Remicade\u00ae] or conventional therapy. J Crohns Colitis. 2017;11(6):680\u20139.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"4065_CR50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12624","volume":"39","author":"CJ Williams","year":"2014","unstructured":"Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(5):447\u201358.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"4065_CR51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2036.2009.04206.x","volume":"31","author":"Y Zabana","year":"2010","unstructured":"Zabana Y, Dom\u00e8nech E, Ma\u00f1osa M, Garcia-Planella E, Bernal I, Cabr\u00e9 E, et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther. 2010;31(5):553\u201360.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"4065_CR52","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1517\/14740338.2015.1029915","volume":"14","author":"R Khanna","year":"2015","unstructured":"Khanna R, Feagan BG. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opin Drug Saf. 2015;14(6):987\u201397.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"4065_CR53","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"4065_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1365-2036.16.s4.1.x","volume":"16","author":"F Rizzello","year":"2002","unstructured":"Rizzello F, Gionchetti P, Venturi A, Amadini C, Romagnoli R, Campieri M. Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ther. 2002;16(Suppl 4):3\u20136.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"4065_CR55","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2174\/138945012802429750","volume":"13","author":"A Schirbel","year":"2012","unstructured":"Schirbel A, Sturm A. Imaging in inflammatory bowel disease mucosal healing in ulcerative colitis: relevance for clinical outcomes. Curr Drug Targets. 2012;13(10):1234\u201344.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"4065_CR56","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","volume":"141","author":"JF Colombel","year":"2011","unstructured":"Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194\u2013201.","journal-title":"Gastroenterology"},{"issue":"6","key":"4065_CR57","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.13948","volume":"45","author":"L Vuitton","year":"2017","unstructured":"Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, de Pineton CG, Walsh AJ, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45(6):801\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"4065_CR58","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/ibd.21925","volume":"18","author":"JE Baars","year":"2012","unstructured":"Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012;18(9):1634\u201340.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"4065_CR59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cgh.2018.06.015","volume":"17","author":"N Narula","year":"2019","unstructured":"Narula N, Alshahrani AA, Yuan Y, Reinisch W, Colombel JF. Patient-reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(3):411-8.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"4065_CR60","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/gutjnl-2012-304066","volume":"63","author":"M Vivinus-N\u00e9bot","year":"2014","unstructured":"Vivinus-N\u00e9bot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63(5):744\u201352.","journal-title":"Gut"},{"issue":"2","key":"4065_CR61","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1582-4934.2011.01298.x","volume":"16","author":"N Bernardini","year":"2012","unstructured":"Bernardini N, Segnani C, Ippolito C, De Giorgio R, Colucci R, Faussone-Pellegrini MS, et al. Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med. 2012;16(2):318\u201327.","journal-title":"J Cell Mol Med"},{"issue":"7\u20138","key":"4065_CR62","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3109\/00365521.2011.579156","volume":"46","author":"EA van Hoboken","year":"2011","unstructured":"van Hoboken EA, Thijssen AY, Verhaaren R, van der Veek PP, Prins FA, Verspaget HW, et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol. 2011;46(7\u20138):981\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"4065_CR63","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2013.02.030","volume":"11","author":"L Rosenberg","year":"2013","unstructured":"Rosenberg L, Nanda KS, Zenlea T, Gifford A, Lawlor GO, Falchuk KR, et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gastroenterol Hepatol. 2013;11(8):991\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"4065_CR64","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1136\/gutjnl-2016-312307","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Keir ME, Scherl A, Zhao R, de Hertogh G, Faubion WA, et al. Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. Gut. 2017;66(12):2063\u20138.","journal-title":"Gut"},{"key":"4065_CR65","doi-asserted-by":"publisher","first-page":"109545","DOI":"10.1016\/j.intimp.2022.109545","volume":"114","author":"C Dai","year":"2023","unstructured":"Dai C, Huang YH, Jiang M. Combination therapy in inflammatory bowel disease: current evidence and perspectives. Int Immunopharmacol. 2023;114:109545.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4065_CR66","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00384-023-04378-w","volume":"38","author":"B Han","year":"2023","unstructured":"Han B, Tang D, Lv X, Li S, Fan J, Xu X, et al. Comparative efficacy and safety of combination therapy with infliximab for Crohn\u2019s disease: a systematic review and network meta-analysis. Int J Colorectal Dis. 2023;38(1):82.","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"4065_CR67","first-page":"E140","volume":"64","author":"T Otsuka","year":"2018","unstructured":"Otsuka T, Ooi M, Tobimatsu K, Wakahara C, Watanabe D, Adachi S, et al. Short-term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: retrospective observational study. Kobe J Med Sci. 2018;64(4):E140\u20138.","journal-title":"Kobe J Med Sci"},{"issue":"10","key":"4065_CR68","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","volume":"4","author":"EA Maser","year":"2006","unstructured":"Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2006;4(10):1248\u201354.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04065-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:04:01Z","timestamp":1751357041000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04065-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4065"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04065-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"458"}}